Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
/in Dendritic Cells, Glioblastoma, International Publications, IOZK VeröffentlichungenAntitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease VirusClinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination
/in Dendritic Cells, Glioblastoma, International PublicationsVaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma
/in Dendritic Cells, Glioblastoma, International PublicationsTransient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications, IOZK VeröffentlichungenMTH-68/H oncolytic viral treatment in human high-grade gliomas
/in Glioblastoma, International Publications, Newcastle Disease VirusVaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
/in Dendritic Cells, Glioblastoma, International PublicationsThe history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International PublicationsHuman tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis
/in Breast Cancer, Colorectal Cancer, Glioblastoma, International Publications, Newcastle Disease Virus
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer